United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Search entities
Discover all 32,649 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 2286,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "f3c0d53c-7213-4644-b919-5b3dbb4ee409",
"title": "Mayville Engineering Company, Inc. (MEC) Seals $140M Accu-Fab Acquisition Deal",
"description": "Mayville Engineering Company, Inc. (NYSE:MEC) has reached a definitive agreement to acquire Accu-Fab Inc. from Tide Rock Holdings LLC for $140.5 million.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/mayville-engineering-company-inc-mec-seals-140m-accu-fab-acquisition-deal-1541891/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/11/13141457/MEC-insidermonkey-1699902893699.jpg",
"language": "en",
"published_at": "2025-05-28T00:43:35.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "MEC",
"name": "Mayville Engineering Company, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 170.65099,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Mayville</em> <em>Engineering</em> <em>Company</em>, <em>Inc</em>. (MEC) Seals $140M Accu-Fab Acquisition Deal",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "060b81a3-4c03-4cb1-937b-f8f8e81b46e7",
"title": "WiseTech Acquires E2open Parent Holdings, Inc. (ETWO) in $2.1 Billion Software Deal",
"description": "The cloud-based supply chain software provider, E2open Parent Holdings, Inc.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/wisetech-acquires-e2open-parent-holdings-inc-etwo-in-2-1-billion-software-deal-1541097/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/10/15214625/ETWO-insidermonkey-1697420783463.jpg",
"language": "en",
"published_at": "2025-05-28T00:33:34.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "ETWO",
"name": "E2open Parent Holdings, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 182.98839,
"sentiment_score": 0,
"highlights": [
{
"highlight": "WiseTech Acquires <em>E2open</em> <em>Parent</em> <em>Holdings</em>, <em>Inc</em>. (ETWO) in $2.1 Billion Software Deal",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "ETWO-WT",
"name": "E2open Parent Holdings, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 182.98839,
"sentiment_score": 0,
"highlights": [
{
"highlight": "WiseTech Acquires <em>E2open</em> <em>Parent</em> <em>Holdings</em>, <em>Inc</em>. (ETWO) in $2.1 Billion Software Deal",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "627f0692-cd31-4d9f-8636-4e4e1cba9e43",
"title": "Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408",
"description": "Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment...",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/teva-pharmaceutical-industries-limited-teva-wins-fda-fast-track-for-celiac-disease-drug-tev-53408-1542137/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/11/09210828/ABEO-insidermonkey-1699582105955.jpg",
"language": "en",
"published_at": "2025-05-28T00:25:31.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEVA",
"name": "Teva Pharmaceutical Industries Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 173.26607,
"sentiment_score": 0.5719,
"highlights": [
{
"highlight": "<em>Teva</em> <em>Pharmaceutical</em> <em>Industries</em> <em>Limited</em> (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408",
"sentiment": 0.5719,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "2752e902-95f4-4c2a-8e32-09941612aadf",
"title": "HDV: This Core High Dividend ETF Is Back On My Watchlist (NYSEARCA:HDV)",
"description": "The iShares Core High Dividend ETF has 3.48% yield, low beta, and market safety compared to SCHD, FDVV, SPYD & DHS. See more on HDV ETF here.",
"keywords": "",
"snippet": "I last reviewed the iShares Core High Dividend ETF (NYSEARCA: HDV ) on November 19, 2023, where I expressed caution over its 22% allocation to Energy stocks des...",
"url": "https://seekingalpha.com/article/4790295-hdv-this-core-high-dividend-etf-is-back-on-my-watchlist",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/571606663/image_571606663.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-05-28T00:24:46.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "HDV",
"name": "iShares Core High Dividend ETF",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "etf",
"industry": "N/A",
"match_score": 138.42247,
"sentiment_score": 0.06945,
"highlights": [
{
"highlight": "I last reviewed the <em>iShares</em> <em[+228 characters]",
"sentiment": 0.1389,
"highlighted_in": "main_text"
},
{
"highlight": "HDV: This Core High Dividend ETF Is Back On My Watchlist (<em>NYSEARCA:HDV</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "d608ee38-1e31-40d7-8aef-c40479dbab36",
"title": "Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death",
"description": "Rocket Pharmaceuticals, Inc.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/rocket-pharmaceuticals-inc-rckt-gene-therapy-trial-paused-following-patient-death-1542127/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/10/31023834/MGTX-insidermonkey-1698734312618.jpg",
"language": "en",
"published_at": "2025-05-28T00:01:45.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "RCKT",
"name": "Rocket Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 117.21097,
"sentiment_score": -0.5994,
"highlights": [
{
"highlight": "<em>Rocket</em> <em>Pharmaceuticals</em>, <em>Inc</em>. (RCKT) Gene Therapy Trial Paused Following Patient Death",
"sentiment": -0.5994,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "2cd85fe3-86fa-4fdb-917e-ab9ac01be55c",
"title": "Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal",
"description": "Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/biogen-inc-biib-taps-rnai-therapy-in-city-therapeutics-deal-1542119/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/12181054/MRNA-imagemaker-1694556652818.jpg",
"language": "en",
"published_at": "2025-05-27T23:58:55.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "BIIB",
"name": "Biogen Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 83.3051,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Biogen</em> <em>Inc</em>. (BIIB) Taps RNAi Therapy in City Therapeutics Deal",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "c9916492-56fb-4451-9a6a-6a3be3fb9383",
"title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network",
"description": "NRx Pharmaceuticals, Inc.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/nrx-pharmaceuticals-inc-nasdaqnrxp-acquires-kadima-institute-to-launch-100m-psychiatry-clinic-network-1542114/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/12/09075839/IPHA-insidermonkey-1702126718038.jpg",
"language": "en",
"published_at": "2025-05-27T23:56:28.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "NRXP",
"name": "NRx Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 174.32776,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>NRx</em> <em>Pharmaceuticals</em>, <em>Inc</em>. (<em>NASDAQ:NRXP</em>) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "0c8e5195-c4c6-4a70-a0ee-b21707ffaac5",
"title": "Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025",
"description": "Myriad Genetics, Inc.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/myriad-genetics-inc-mygn-showcases-breakthrough-mrd-data-and-ai-driven-cancer-tools-at-asco-2025-1542112/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/10/15194007/ALLO-insidermonkey-1697413205435.jpg",
"language": "en",
"published_at": "2025-05-27T23:53:44.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "MYGN",
"name": "Myriad Genetics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 131.7239,
"sentiment_score": -0.6597,
"highlights": [
{
"highlight": "<em>Myriad</em> <em>Genetics</em>, <em>Inc</em>. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "9e460ae6-c875-42b6-8ba4-04234627b2a1",
"title": "Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting",
"description": "**media[638495]**",
"keywords": "Myriad, Genetics, Highlights, New, Research, Advancements, and, Oncology, Innovations, at, 2025, ASCO, Annual, Meeting",
"snippet": "Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators\n\nSALT LAKE CITY, May 27...",
"url": "https://www.manilatimes.net/2025/05/28/tmt-newswire/globenewswire/myriad-genetics-highlights-new-research-advancements-and-oncology-innovations-at-2025-asco-annual-meeting/2121958",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/05/28/638495.png",
"language": "en",
"published_at": "2025-05-27T20:13:20.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "0K3W.L",
"name": "Myriad Genetics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 73.28592,
"sentiment_score": 0.297514,
"highlights": [
{
"highlight": "Two Molecular Residual Disease (MRD) stu[+195 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "concurrent pathogenic variants in BRCA1 [+335 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Genetics</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "We continue to build upon this foundatio[+247 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Myriad</em> <em>Genetics</em>\n[+161 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Myriad</em> <em>Genetics</em> develo[+293 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Myriad</em> <em>Genetics</em> Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "MYGN",
"name": "Myriad Genetics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 83.82145,
"sentiment_score": 0.297325,
"highlights": [
{
"highlight": "Two Molecular Residual Disease (MRD) stu[+195 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>MYGN</em>), a lead[+221 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "concurrent pathogenic variants in BRCA1 [+335 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Genetics</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "We continue to build upon this foundatio[+247 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Myriad</em> <em>Genetics</em>\n[+161 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Myriad</em> <em>Genetics</em> develo[+293 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Myriad</em> <em>Genetics</em> Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "MYD.DE",
"name": "Myriad Genetics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 73.265945,
"sentiment_score": 0.297514,
"highlights": [
{
"highlight": "Two Molecular Residual Disease (MRD) stu[+195 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "concurrent pathogenic variants in BRCA1 [+335 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Genetics</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "We continue to build upon this foundatio[+247 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Myriad</em> <em>Genetics</em>\n[+161 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Myriad</em> <em>Genetics</em> develo[+293 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Myriad</em> <em>Genetics</em> Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "59737a44-3ff4-4b86-ad19-3b8a44d56960",
"title": "Musk Must Face Suit Challenging Power as Trump Aide, Judge Says",
"description": "Elon Musk will have to face a lawsuit that claims the billionaire is wielding illegal power by orchestrating President Donald Trump’s dramatic cuts in federal government jobs and spending, a judge ruled.",
"keywords": "Elon Musk, lawsuit, Donald Trump, federal government jobs, DOGE",
"snippet": "Elon Musk will have to face a lawsuit that claims the billionaire is wielding illegal power by orchestrating President Donald Trump’s dramatic cuts in federal...",
"url": "https://www.livemint.com/companies/news/musk-must-face-suit-challenging-power-as-trump-aide-judge-says-11748389801586.html",
"image_url": "https://www.livemint.com/lm-img/img/2024/12/06/1600x900/company_1_1733464951182_1733464958176.png",
"language": "en",
"published_at": "2025-05-27T23:50:01.000000Z",
"source": "livemint.com",
"relevance_score": null,
"entities": [
{
"symbol": "TSLA",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 16.457352,
"sentiment_score": -0.0772,
"highlights": [
{
"highlight": "Musk said last month he’ll cut back si[+228 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "35438004-e6c6-46d3-81b5-fa2ea8e22e25",
"title": "Walmart Inc. (WMT) Fined for Letting Third-Party Sellers Ship Realistic Toy Guns to New York",
"description": "Walmart Inc.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/walmart-inc-wmt-fined-for-letting-third-party-sellers-ship-realistic-toy-guns-to-new-york-1542040/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2016/02/09121619/shutterstock_152288732.jpg",
"language": "en",
"published_at": "2025-05-27T23:48:28.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "WMT",
"name": "Walmart Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 57.436768,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Walmart</em> <em>Inc</em>. (WMT) Fined for Letting Third-Party Sellers Ship Realistic Toy Guns to New York",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 3557,
"sentiment_avg": 0.28867628447271865
}
]
}
Other details
Entity count
- 32,649